111 related articles for article (PubMed ID: 12704897)
1. [Development of primary malignancies after liver and kidney transplantation and the treatment approach].
Bechstein WO; Dette K; Golling M; Wullstein Ch
Kongressbd Dtsch Ges Chir Kongr; 2002; 119():398-404. PubMed ID: 12704897
[TBL] [Abstract][Full Text] [Related]
2. Burden of de novo malignancy in the liver transplant recipient.
Chandok N; Watt KD
Liver Transpl; 2012 Nov; 18(11):1277-89. PubMed ID: 22887956
[TBL] [Abstract][Full Text] [Related]
3. De Novo Malignancies After Transplantation: Risk and Surveillance Strategies.
Doycheva I; Amer S; Watt KD
Med Clin North Am; 2016 May; 100(3):551-67. PubMed ID: 27095645
[TBL] [Abstract][Full Text] [Related]
4. Malignancies in renal transplantation: an unmet medical need.
Dantal J; Pohanka E
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i4-10. PubMed ID: 17456618
[TBL] [Abstract][Full Text] [Related]
5. Tumours after kidney transplantation.
Lutz J; Heemann U
Curr Opin Urol; 2003 Mar; 13(2):105-9. PubMed ID: 12584469
[TBL] [Abstract][Full Text] [Related]
6. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
[TBL] [Abstract][Full Text] [Related]
7. National survey of de novo malignancy after solid organ transplantation in Japan.
Miyazaki T; Sato S; Kondo T; Kusaka M; Gotoh M; Saiki Y; Ono M; Kokudo N; Enosawa S; Satoh S; Soeda E; Furukawa H; Kobayashi E; Nagayasu T
Surg Today; 2018 Jun; 48(6):618-624. PubMed ID: 29380136
[TBL] [Abstract][Full Text] [Related]
8. Post-transplant lymphoproliferative disorder after kidney transplantation: time to adopt monitoring of Epstein-Barr virus?
Biller P; Michaux L; Pauw LD; Camboni A; Mourad M; Kanaan N
Acta Clin Belg; 2015 Jun; 70(3):218-22. PubMed ID: 25541210
[TBL] [Abstract][Full Text] [Related]
9. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
10. [Malignant neoplasias in renal transplantation recipients].
Gómez-Roel X; León-Rodríguez E
Rev Invest Clin; 2005; 57(2):225-9. PubMed ID: 16524062
[TBL] [Abstract][Full Text] [Related]
11. New concepts and best practices for management of pre- and post-transplantation cancer.
Campistol JM; Cuervas-Mons V; Manito N; Almenar L; Arias M; Casafont F; Del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Román A; Serón D; Ussetti P;
Transplant Rev (Orlando); 2012 Oct; 26(4):261-79. PubMed ID: 22902168
[TBL] [Abstract][Full Text] [Related]
12. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.
Klintmalm GB; Saab S; Hong JC; Nashan B
Clin Transplant; 2014 Jun; 28(6):635-48. PubMed ID: 24628264
[TBL] [Abstract][Full Text] [Related]
13. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
[TBL] [Abstract][Full Text] [Related]
14. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
[TBL] [Abstract][Full Text] [Related]
15. [Early diagnosis and comprehensive treatments of post-transplantation lymphoproliferative disorder after pediatric liver transplantation].
Deng Z; Jiang L; Zhou T; Shen C; Chen Q; Xia Q
Zhonghua Er Ke Za Zhi; 2014 Aug; 52(8):579-82. PubMed ID: 25224233
[TBL] [Abstract][Full Text] [Related]
16. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
17. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
[TBL] [Abstract][Full Text] [Related]
18. [Solid tumors after kidney transplantation].
Moal MC
Nephrol Ther; 2008 Oct; 4 Suppl 3():S214-7. PubMed ID: 19000890
[TBL] [Abstract][Full Text] [Related]
19. De-novo malignancies after kidney transplantation: A long-term observational study.
Fröhlich FA; Halleck F; Lehner L; Schrezenmeier EV; Naik M; Schmidt D; Khadzhynov D; Kast K; Budde K; Staeck O
PLoS One; 2020; 15(11):e0242805. PubMed ID: 33253202
[TBL] [Abstract][Full Text] [Related]
20. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
Mihalov ML; Gattuso P; Abraham K; Holmes EW; Reddy V
Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
